In 2022, the US Federal Trade Commission (FTC) launched an inquiry into the opaque business practices of pharmacy benefit managers (PBMs), which act as intermediaries between drug manufacturers, insurance plans, and pharmacies. Now, despite “delay tactics” from PBMs, the FTC recently published an interim report describing how these companies might harm patients’ ability to access and afford their prescription medications.
